TYMLOS (abaloparatide) a synthetic peptide analog of hPTHrP (human parathyroid hormone-related protein) that is an anabolic agent – meaning it increases bone formation. In clinical trials, Tymlos was shown to reduce the risk of vertebral fractures and nonvertebral fractures. It is reserved for the treatment of postmenopausal women with osteoporosis who are at high risk for having a fracture or who have failed or are intolerant to other available osteoporosis therapy.
What are the side effects of abaloparatide?
The most common side effects are excess of calcium in the urine, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain and vertigo.